XC-302 free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529432

CAS#: 916890-10-3

Description: XC-302, also called Puquitinib, is a multi-targeted inhibitor that induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells.


Price and Availability

Size
Price

Size
Price

Size
Price

XC-302 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 529432
Name: XC-302 free base
CAS#: 916890-10-3
Chemical Formula: C17H15N7
Exact Mass: 317.1389
Molecular Weight: 317.35
Elemental Analysis: C, 64.34; H, 4.76; N, 30.90


Synonym: XC-302; XC302; XC 302; Puquitinib

IUPAC/Chemical Name: N6-cyclopropyl-N2-(quinolin-6-yl)-9H-purine-2,6-diamine

InChi Key: QUTFBURLXCODBH-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H15N7/c1-2-10-8-12(5-6-13(10)18-7-1)22-17-23-15-14(19-9-20-15)16(24-17)21-11-3-4-11/h1-2,5-9,11H,3-4H2,(H3,19,20,21,22,23,24)

SMILES Code: C1(NC2=NC(NC3CC3)=C(N=CN4)C4=N2)=CC=C5C(C=CC=N5)=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Wang KF, Yang H, Jiang WQ, Li S, Cai YC. Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells. Int J Mol Med. 2015 Dec;36(6):1556-62. doi: 10.3892/ijmm.2015.2378. PubMed PMID: 26499488; PubMed Central PMCID: PMC4678157.

2: Yang H, Wang Y, Zhan J, Xia Y, Sun P, Bi XW, Liu PP, Li ZM, Li S, Zou BY, Jiang WQ. Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma. Oncotarget. 2015 Dec 22;6(41):44049-56. doi: 10.18632/oncotarget.5833. PubMed PMID: 26510909; PubMed Central PMCID: PMC4791286.